Measure Summary Report

Evaluation Date : 6/25/2025		CMS 347v8 Statin Therapy	
		CMS 347v8 Statin Therapy	CMS347v8 DEM1
Measure Start Date: 1/1/2025	**Measure End Date: 12/31/2025**	Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR *Patients aged 20 to 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR *Patients aged 40-75 years with a diagnosis of diabetes; OR *Patients aged 40 to 75 with a 10-year ASCVD risk score of >= 20 percent	Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure.
Geetha Reddy		88.05 % (339 / 385)	88.12 % (267 / 303)
GEETHA M REDDY MD F A C C		88.05 % (339/385)	88.12 % (267/303)

Denominator count reported is less Total Exclusions which are not reported. Please see Summary report for independent and total Exclusion counts necessary for CMS Attestation.

i   Inverse Measure

nextgen. healthcare

Measure Summary Report

CMS 347v8 Statin Therapy		
CMS347v8 DEM2	**CMS347v8 DEM3**	**CMS347v8 DEM4**
Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *Patients aged 20 to 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia.	Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *Patients aged 40-75 years with a diagnosis of diabetes.	Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *Patients aged 40 to 75 with a 10-year ASCVD risk score of >= 20 percent.
100 % (1 / 1)	87.65 % (71 / 81)	0 % (0 / 0)
100 % (1/1)	87.65 % (71/81)	0 % (0/0)

Measure Summary Report

CMS 50v13 Closing Referral Loop	CMS 22v13 BP Screening and Follow Up	CMS 165v13 Controlling High Blood Pressure
CMS 50v13 Closing Referral Loop	CMS 22v13 BP Screening and Follow Up	CMS 165v13 Controlling High Blood Pressure
Percentage of patients with referrals, regardless of age, for which the referring clinician receives a report from the clinician to whom the patient was referred	Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive	Percentage of patients 18-85 years of age who had a diagnosis of essential hypertension starting before and continuing into, or starting during the first six months of the measurement period, and whose most recent blood pressure was adequately controlled (<140/90mmHg) during the measurement period
0 % (0 / 5)	46.56 % (196 / 421)	87.89 % (537 / 611)
0 % (0/5)	46.56 % (196/421)	87.89 % (537/611)

i Inverse Measure

Measure Summary Report

CMS 2v14 Depression Screening and Follow Up	CMS 144v13 (NQF 0083e) HF Beta-Blocker Therapy for LVSD	CMS 156v13 Use of High-Risk Medications in Older Adults
		i
CMS 2v14 Depression Screening and Follow Up	CMS 144v13 (NQF 0083e) HF Beta-Blocker Therapy for LVSD	CMS 156v13 Use of High-Risk Medications in Older Adults
Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter	Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) <= 40% who were prescribed or already taking beta-blocker therapy during the measurement period	Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. Three rates are reported. 1. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. 2. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class, except for appropriate diagnoses. 3. Total rate (the sum of the two numerators divided by the denominator, deduplicating for patients in both numerators).
95.42 % (834 / 874)	100 % (4 / 4)	0.36 % (2 / 551)
95.42 % (834/874)	100 % (4/4)	0.36 % (2/551)

i Inverse Measure

Measure Summary Report

CMS 156v13 Use of High-Risk Medications in Older Adults		
i		
CMS 156v13_NUM1	CMS 156v13_NUM2	CMS 156v13_NUM3
Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. Three rates are reported. 1. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. 2. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class, except for appropriate diagnoses. 3. Total rate (the sum of the two numerators divided by the denominator, deduplicating for patients in both numerators).	Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. Three rates are reported. 1. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. 2. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class, except for appropriate diagnoses. 3. Total rate (the sum of the two numerators divided by the denominator, deduplicating for patients in both numerators).	Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. Three rates are reported. 1. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class. 2. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class, except for appropriate diagnoses. 3. Total rate (the sum of the two numerators divided by the denominator, deduplicating for patients in both numerators).
0.36 % (2 / 551)	0 % (0 / 551)	0.36 % (2 / 551)
0.36 % (2/551)	0 % (0/551)	0.36 % (2/551)

Measure Summary Report

CMS 90v14 Functional Status Assessments for Heart Failure	CMS 145v13 (NQF 0070e) CAD Beta-Blocker for Prior MI or LVSD	
CMS 90v14 FSA Congestive Heart Failure	CMS 145v13 (NQF 0070e) CAD Beta-Blocker for Prior MI or LVSD	CMS 145v13 NUM1
Percentage of patients 18 years of age and older with heart failure who completed initial and follow-up patient-reported functional status assessments	Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed beta-blocker therapy	Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed beta-blocker therapy
0 % (0 / 42)	100 % (12 / 12)	100 % (12 / 12)
0 % (0/42)	100 % (12/12)	100 % (12/12)

Measure Summary Report

CMS 145v13 (NQF 0070e) CAD Beta-Blocker for Prior MI or LVSD	CMS 135v13 (NQF 0081e) HF: ACE or ARB or ARNI Therapy for LVSD	CMS 68v14 Documentation of Current Medications in the Medical Record
CMS 145v13 NUM2	CMS 135v13 (NQF 0081e) HF: ACE or ARB or ARNI Therapy for LVSD	CMS 68v14 Documentation of Current Medications in the Medical Record
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed beta-blocker therapy	Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed or already taking ACE inhibitor or ARB or ARNI therapy during the measurement period.	Percentage of visits for which the eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter
0 % (0 / 0)	88.89 % (8 / 9)	97.74 % (1298 / 1328)
0 % (0/0)	88.89 % (8/9)	97.74 % (1298/1328)

Measure Summary Report

CMS 138v13 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention		
CMS 138v13 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	**CMS 138v13 NUM1**	**CMS 138v13 NUM2**
Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.

Three rates are reported:
a. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period
b. Percentage of patients aged 12 years and older who were identified as a tobacco user during the measurement period who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period
c. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user | Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.   Three rates are reported: a. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period b. Percentage of patients aged 12 years and older who were identified as a tobacco user during the measurement period who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period c. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user | Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.   Three rates are reported: a. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period b. Percentage of patients aged 12 years and older who were identified as a tobacco user during the measurement period who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period c. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user |
| 97.67 % (336 / 344) | 97.67 % (336 / 344) | 76.67 % (23 / 30) |
| 97.67 % (336/344) | 97.67 % (336/344) | 76.67 % (23/30) |

Measure Summary Report

CMS 138v13 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
CMS 138v13 NUM3
Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.   Three rates are reported: a. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period b. Percentage of patients aged 12 years and older who were identified as a tobacco user during the measurement period who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period c. Percentage of patients aged 12 years and older who were screened for tobacco use one or more times during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user
96.51 % (332 / 344)
96.51 % (332/344)

i Inverse Measure